carbapenems has been researched along with cefepime in 71 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (cefepime) | Trials (cefepime) | Recent Studies (post-2010) (cefepime) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 1,737 | 186 | 684 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (2.82) | 18.2507 |
2000's | 17 (23.94) | 29.6817 |
2010's | 30 (42.25) | 24.3611 |
2020's | 22 (30.99) | 2.80 |
Authors | Studies |
---|---|
Devalckenaere, A; Husson, MO; Izard, D; Vachée, A | 1 |
Verbist, L; Verhaegen, J | 1 |
Jacolot, A; Leotard, S; Louchahi, K; Mimoz, O; Nordmann, P; Padoin, C; Petitjean, O | 1 |
Bantar, C; Di Chiara, M; Nicola, F; Relloso, S; Smayevsky, J | 1 |
Christenson, JC; Daly, JA; Korgenski, EK | 1 |
Barry, AL; Brown, SD; Fuchs, PC | 1 |
Endo, H; Jinbo, K; Nishinari, C; Suzuki, Y; Tamura, C | 1 |
Gondoh, H; Hanada, S; Ikeda, S; Imamura, Y; Izumi, Y; Kawano, F; Masuda, M; Matsuishi, E; Matsuoka, H; Okamura, S; Saburi, Y; Shibuya, T; Tamura, K; Tsukada, J; Uike, N; Utsunomiya, A | 1 |
Biedenbach, DJ; Gales, AC; Jones, RN | 1 |
Song, A | 1 |
Bernabéu-Wittel, M; de Cueto, M; del Carmen Conejo, M; García, I; Jiménez-Mejías, ME; Martínez-Martínez, L; Pachón, J; Pachón-Ibáñez, ME; Pascual, A; Pichardo, C | 1 |
Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
Baraniak, A; Bossaert, L; Demey, HE; Gniadkowski, M; Goethaert, K; Goossens, H; Ieven, M; Jansens, H; Jorens, PG; Lammens, C; Van Herck, K; Van Looveren, M | 1 |
Fernández-Cuenca, F; Martínez-Martínez, L; Pascual, A; Rodríguez-Martínez, JM | 1 |
Cheng, KC; Chuang, YC; Huang, GC; Wu, LT; Yu, WL | 1 |
Kawano, F; Koga, S; Matsuoka, H; Okamura, S; Shibata, K; Shirahashi, A; Suzushima, H; Tamura, K; Tsukamoto, A; Uozumi, K; Yamashita, K | 1 |
Chai, D; Li, Z; Pei, F; Tong, W; Wang, R | 1 |
Alp, E; Aygen, B; Metan, G; Sumerkan, B | 1 |
Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F | 1 |
Amicosante, G; Falcone, M; Mancini, C; Mezzatesta, ML; Perilli, M; Stefani, S; Venditti, M | 1 |
Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC | 1 |
Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA | 1 |
Cabot, G; Macia, MD; Martínez-Martínez, L; Moya, B; Ocampo-Sosa, AA; Oliver, A; Peña, C; Rodríguez, C; Suárez, C; Tubau, F; Zamorano, L | 1 |
Beloborodov, VB; Gruver, KP; Kuz'menko, TN | 1 |
Acosta, F; Cottagnoud, M; Cottagnoud, P; Egerman, U; Laeuffer, JM; Stucki, A | 1 |
Hino, M; Kanamaru, A; Masaoka, T; Nakagawa, Y; Ohta, K; Ohyashiki, K; Suzuki, K; Tamura, K; Urabe, A | 1 |
Hsueh, PR; Huang, WH; Ko, WC; Lee, CC; Lee, NY; Tsui, KC | 1 |
Chen, JH; He, YQ; Liu, S; Wan, YF; Xu, CQ; Ye, ML; Zheng, YL; Zhou, LY | 1 |
Goff, DA; Nicolau, DP | 1 |
Baghdady, N; Ferraro, MJ; Galar, A; Guzmán-Suarez, BB; Hooper, DC; Kubiak, DW; Marty, FM; O'Brien, TF; Siedner, MJ | 1 |
Wu, H; Xie, W; Ye, Z; Zhang, W; Zhao, C | 1 |
Achkar, M; Charrouf, FO; Dabboussia, F; Hamze, M; Mallat, H | 1 |
Bethel, CR; Bonomo, RA; Doi, Y; Endimiani, A; Kasraian, S; Pires, J; Sendi, P; Taracila, M; Tinguely, R | 1 |
Chang, CM; Chen, PL; Ko, WC; Lee, CC; Lee, NY; Li, CW; Li, MC | 1 |
Abdile, AA; Doi, Y; Harris, PN; Huh, K; Huxley, RR; O'Neal, CS; Pandeya, N; Paterson, DL; Paynter, S; Shen, AW; Talbot, TR; Wei, JY | 1 |
Cao, B; Chen, H; Chen, X; Chu, Y; Guo, P; Hu, B; Hu, Z; Jin, Y; Liao, K; Liu, W; Liu, Y; Luo, Y; Su, D; Tian, B; Wang, H; Wang, Y; Wang, Z; Xu, X; Zeng, J; Zhang, F; Zhang, R; Zhao, C; Zhou, C; Zhou, H; Zhuo, C; Zou, M | 1 |
Berrio, I; Castro, B; Maldonado, N; Manjarrés, M; Robledo, C; Robledo, J | 1 |
Estes, LL; Narayanan, PP; Patel, R; Rivera, CG | 1 |
Higuchi, H; Horikoshi, Y; Isogai, M; Ito, K; Shoji, T; Suwa, J | 1 |
Badal, RE; Biedenbach, DJ; Giao, PT; Hung Van, P; Phuong, DM; Su Minh Tuyet, N; Thi Thanh Nga, T; Vu Trung, N | 1 |
Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
Falagas, ME; Legakis, NJ; Skalidis, T; Vardakas, KZ | 1 |
Falagas, ME; Kofteridis, DP; Maraki, S; Mavromanolaki, VE; Perdikis, D; Samonis, G; Vardakas, KZ | 1 |
Hollenberg, SM; Khan, ZA | 1 |
Fisher, K; Juang, P; Kollef, MH; Micek, ST; Trupka, T | 1 |
Altshuler, J; Fedorenko, M; Kim, SA; Paris, D | 1 |
Kim, JH; Kim, MJ; Kim, SB; Sohn, JW; Suh, JW; Yang, KS; Yoon, YK | 1 |
Bland, CM; Chastain, DB; Cretella, DA; White, BP | 1 |
Almirante, B; Escolà-Vergé, L; González-López, JJ; Larrosa, N; Len, O; Los-Arcos, I; Pigrau, C; Viñado, B | 1 |
Cheok, SJH; Chew, KL; Heng, ST; Lye, DC; Ng, TM; Ng, WHW; Tambyah, PA; Tan, SH; Wan, S; Wu, JE; Yap, MY; Yong, J | 1 |
Dang, B; Li, Z; Ma, S; Xu, Z; Zhang, H | 1 |
Akazawa, M; Fukuda, H; Mimura, W | 1 |
Chen, PL; Ko, WC; Lee, NY; Li, CW; Li, MC; Lo, CL; Syue, LS | 1 |
Heo, BY; Jo, DY; Kwon, J; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yeon, SH; Yun, HJ | 1 |
de La Blanchardière, A; Guérin, F; Le Hello, S; Meurant, A; Saint-Lorant, G | 1 |
Bassetti, M; Giacobbe, DR | 1 |
Carvalhaes, CG; Castanheria, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
Mensa, J; Soriano, A | 1 |
Maseda, E; Suárez de la Rica, A | 1 |
Abdulhemid Said, L; Muhsin, EA; Sajid Al-Jubori, S | 1 |
Hishinuma, T; Kirikae, T; Shimojima, M; Shintani, M; Suzuki, M; Tada, T; Tohya, M | 1 |
Gill, CM; Nicolau, DP | 2 |
Banaei, N; Bounthavong, M; Deresinski, S; Diep, C; Ha, D; Lu, B; Wong, M | 1 |
Abdurahim, SA; Alameen, AA; Aloufi, AS; Elsayim, R; Eltayb, WA; Modafer, Y | 1 |
Bercot, B; Bernier, J; Bleibtreu, A; Chaibi, K; Contejean, A; Cuzon, G; Delory, T; El Alaoui, F; Escaut, L; Joseph, A; Lafaurie, M; Maillard, A; Molina, JM; Paccoud, O; Poupet, H; Robert, J; Surgers, L; Tankovic, J; Villa, A | 1 |
Chen, J; Jia, W; Jing, R; Li, J; Liu, Y; Sun, G; Sun, H; Wang, T; Xu, X; Xu, Y; Zhang, G | 1 |
Boyer, P; Danion, F; Gravet, A; Hansmann, Y; Hoellinger, B; Kaeuffer, C; Lefebvre, N; Robert, A; Ruch, Y; Severac, F; Ursenbach, A | 1 |
Asempa, TE; Fouad, A; Gill, CM; Nicolau, DP; Simner, PJ | 1 |
Ávila-Núñez, M; Celestino, P; García-Formoso, L; Garrido-Ventín, M; Lima, O; Martinez-Lamas, L; Pérez-Landeiro, A; Pérez-Rodríguez, MT; Represa, M; Rubianes, M; Rubiñán, P; Sousa, A; Vasallo-Vidal, F | 1 |
Bülow, L; Mecklenburg, M; Meng, Q; Song, C; Sun, X; Wang, Y; Wu, C; Xie, B | 1 |
6 review(s) available for carbapenems and cefepime
Article | Year |
---|---|
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Enzyme Inhibitors; Fever; Humans; Neutropenia; Penicillanic Acid; Penicillins; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2006 |
Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Enterobacteriaceae Infections; Humans; Quinolones; Serratia Infections; Survival Analysis; Treatment Outcome | 2016 |
Valvular Heart Disease in Adults: Infective Endocarditis.
Topics: Anti-Bacterial Agents; Blood Culture; Carbapenems; Cefepime; Cephalosporins; Cross Infection; Echocardiography; Endocarditis; Endocarditis, Bacterial; Gentamicins; Heart Valve Prosthesis; Humans; Prosthesis-Related Infections; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Vancomycin | 2017 |
Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefepime; Enterobacteriaceae; Enterobacteriaceae Infections; Fluoroquinolones; Humans | 2018 |
Mechanism of action of cefiderocol.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cattle; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Gram-Negative Bacteria; Iron; Quinolones; Serine; Tetracyclines | 2022 |
The role of cefiderocol in clinical practice.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
4 trial(s) available for carbapenems and cefepime
Article | Year |
---|---|
Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
Topics: Adult; Algorithms; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Humans; Leukemia; Lymphoma; Male; Neutropenia | 2002 |
High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Critical Illness; Cross Infection; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Treatment Outcome | 2006 |
Efficacy of intravenous ciprofloxacin in patients with febrile neutropenia refractory to initial therapy.
Topics: Adult; Aged; Algorithms; Carbapenems; Cefepime; Cephalosporins; Ciprofloxacin; Female; Fever; Hematologic Diseases; Humans; Male; Middle Aged; Neutropenia; Remission Induction; Salvage Therapy; Treatment Failure; Treatment Outcome | 2006 |
Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Female; Fever; Hematologic Diseases; Humans; Male; Meropenem; Neutropenia; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2013 |
61 other study(ies) available for carbapenems and cefepime
Article | Year |
---|---|
[In vitro study of antibacterial activity of cefepime (Axepim) against gram negative bacteria: comparison with cephalosporins and other beta-lactams].
Topics: Acinetobacter; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporinase; Cephalosporins; Drug Combinations; Drug Resistance, Microbial; Enterobacteriaceae; Hospital Units; In Vitro Techniques; Monobactams; Pseudomonas aeruginosa | 1996 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Drug Resistance, Microbial; Enterobacter cloacae; Enterobacteriaceae Infections; Half-Life; Imipenem; Kidney Diseases; Male; Meropenem; Penicillinase; Pneumonia, Bacterial; Protein Binding; Rats; Rats, Wistar; Thienamycins; Uranyl Nitrate | 2000 |
Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2000 |
In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Thienamycins | 2000 |
Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Diffusion; Enterobacteriaceae; Imipenem; Meropenem; Microbial Sensitivity Tests; Pyrrolidines; Thienamycins | 2001 |
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
Topics: Bacteria; Carbapenems; Cefepime; Cefozopran; Cephalosporins; Imipenem; Meropenem; Thienamycins | 2001 |
Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).
Topics: beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Enterobacter; Klebsiella; Microbial Sensitivity Tests | 2003 |
Retrospective study of clinical outcomes with extended-spectrum beta-lactamases--a different interpretation.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Humans; Retrospective Studies; Time Factors; Treatment Outcome | 2004 |
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Colony Count, Microbial; Guinea Pigs; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Porins; Thienamycins; Treatment Outcome | 2005 |
In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Enterobacter aerogenes; Humans; Microbial Sensitivity Tests; Molecular Sequence Data | 2006 |
Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan.
Topics: Amikacin; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Taiwan | 2006 |
In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Sulbactam | 2006 |
Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.
Topics: Acinetobacter baumannii; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Carbapenems; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurosurgical Procedures; Postoperative Complications; Thienamycins; Turkey | 2007 |
Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefepime; Cefuroxime; Cell Line; Cells, Cultured; Cephalosporins; Cloxacillin; Humans; Hydrogen-Ion Concentration; Imipenem; Meropenem; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Oxacillin; Phagocytosis; Staphylococcus aureus; Thienamycins | 2008 |
Prolonged bacteraemia caused by VIM-1 metallo-beta-lactamase-producing Proteus mirabilis: first report from Italy.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Chromosomes, Bacterial; DNA, Bacterial; Humans; Integrons; Italy; Male; Meropenem; Plasmids; Proteus Infections; Proteus mirabilis; Surgical Wound Infection; Thienamycins; Treatment Failure; Treatment Outcome | 2010 |
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic | 2010 |
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2011 |
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Imipenem; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2011 |
[Actual aspects of sepsis].
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Hospitals; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Retrospective Studies; Russia; Sepsis; Vancomycin | 2011 |
Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Carbapenems; Cefepime; Cephalosporins; Disease Models, Animal; Doripenem; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Meningitis, Bacterial; Rabbits; Treatment Outcome | 2012 |
Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Case-Control Studies; Cefepime; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Treatment Outcome | 2013 |
Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Cross Infection; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pneumonia; Retrospective Studies; Risk Factors | 2013 |
When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Drug Costs; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2013 |
Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefepime; Cephalosporins; Enterobacter; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2014 |
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Drug Resistance; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2014 |
Characterization of resistance genes in 68 ESBL-producing Klebsiella pneumonia in Lebanon.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Colony Count, Microbial; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Lebanon; Microbial Sensitivity Tests; Organ Specificity; Substrate Specificity | 2014 |
In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Ceftriaxone; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Male; Microbial Sensitivity Tests; Molecular Docking Simulation | 2015 |
Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Diabetes Complications; Diabetes Mellitus; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Gene Expression; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Neoplasms; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2015 |
[Analysis of pathogen spectrum and resistance of clinical common organisms causing bloodstream infections, hospital-acquired pneumonia and intra-abdominal infections from thirteen teaching hospitals in 2013].
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefepime; Cephalosporins; China; Cross Infection; Hospitals, Teaching; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Minocycline; Pneumonia; Tigecycline; Vancomycin | 2015 |
Ertapenem resistance in 2 tertiary-care hospitals: Microbiology, epidemiology, and risk factors.
Topics: Aged; Antimicrobial Stewardship; beta-Lactam Resistance; Carbapenems; Case-Control Studies; Cefepime; Colombia; Cross Infection; Diagnosis-Related Groups; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; Risk Factors; Tertiary Care Centers | 2017 |
Impact of Cefepime Susceptible-Dose-Dependent MIC for Enterobacteriaceae on Reporting and Prescribing.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Drug Prescriptions; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests | 2016 |
Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Hospitals; Humans; Japan; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tokyo | 2016 |
Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gentamicins; Humans; Longitudinal Studies; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Tigecycline; Vietnam | 2016 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inpatients; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Pseudomonas aeruginosa; Thienamycins; Tigecycline | 2017 |
In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Child; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacter; Enterobacteriaceae Infections; Greece; Hospitals, University; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tigecycline | 2017 |
Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study.
Topics: Academic Medical Centers; Aged; Anti-Bacterial Agents; Carbapenems; Cefepime; Ceftriaxone; Cephalosporins; Cross-Over Studies; Female; Hospital Mortality; Humans; Intensive Care Units; Male; Middle Aged; Monobactams; Pneumonia; Pneumonia, Ventilator-Associated; Prospective Studies; Quinolones; Respiration, Artificial; Statistics, Nonparametric | 2017 |
Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Retrospective Studies; Urinary Tract Infections | 2018 |
The use of cefepime as a carbapenem-sparing antibiotic for treating uncomplicated acute pyelonephritis caused by extended-spectrum β-lactamase producing Escherichia coli.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Hospitals, University; Humans; Male; Middle Aged; Pyelonephritis; Republic of Korea; Retrospective Studies; Risk Factors; Treatment Outcome | 2018 |
Infections by OXA-48-like-producing Klebsiella pneumoniae non-co-producing extended-spectrum beta-lactamase: Can they be successfully treated with cephalosporins?
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Ceftriaxone; Cephalosporins; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Nephritis; Retrospective Studies; Spain | 2019 |
Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2020 |
Coexistence of the bla
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Drug Resistance, Bacterial; Enterobacteriaceae; Genome, Bacterial; Rivers; Streptomycin | 2020 |
Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cefepime; Cross-Sectional Studies; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Escherichia coli; Female; Hematologic Neoplasms; Humans; Japan; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Young Adult | 2020 |
Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefepime; Drug Therapy, Combination; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged | 2021 |
Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cefepime; Disease-Free Survival; Female; Glycopeptides; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2021 |
Cefepime use: A need for antimicrobial stewardship.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Cefepime; Humans; Retrospective Studies | 2021 |
Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Drug Combinations; Gram-Negative Bacteria; Lactams; Microbial Sensitivity Tests | 2022 |
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cyclooctanes; Enterobacteriaceae; Gram-Negative Bacteria; Hydrazines; Lactams; Microbial Sensitivity Tests; Piperidines; Pseudomonas aeruginosa; Tazobactam | 2022 |
Prevalence of Efflux Pump and Porin-Related Antimicrobial Resistance in Clinical
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefazolin; Cefepime; Cefoxitin; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Iraq; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins; Prevalence | 2022 |
Plasmids Harboring a Tandem Duplicate of
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Humans; Japan; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Phenotype; Pseudomonas aeruginosa; Tazobactam | 2022 |
Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Cefepime; Cefoxitin; Citrobacter freundii; Enterobacter aerogenes; Enterobacter cloacae; Humans; Microbial Sensitivity Tests; Morganella morganii; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Serratia marcescens | 2023 |
Molecular Dynamic Analysis of Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Humans; Imipenem; Klebsiella; Klebsiella pneumoniae; Ligands; Meropenem; Metal Nanoparticles; Microbial Sensitivity Tests; Molecular Dynamics Simulation; Monobactams; Nanoparticles; Pneumonia; Porins; Spectroscopy, Fourier Transform Infrared; Zinc Oxide | 2023 |
Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2023 |
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carbapenems; Cefepime; Microbial Sensitivity Tests; Tigecycline | 2023 |
Cefepime vs carbapenems for treating third-generation cephalosporin-resistant AmpC β-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Enterobacteriaceae; Enterobacteriaceae Infections; Gammaproteobacteria; Humans; Microbial Sensitivity Tests; Retrospective Studies; Sepsis | 2023 |
Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Enterobacteriaceae; Gammaproteobacteria; Humans; Mice; Microbial Sensitivity Tests | 2023 |
Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales.
Topics: Adult; Aged; Bacteremia; Carbapenems; Cefepime; Humans; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis | 2023 |
Activity fingerprinting of AMR β-lactamase towards a fast and accurate diagnosis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefazolin; Cefepime; Humans | 2023 |